This was 2 years ago
LocationOnline
ProgrammesStandICT.eu, which unites the ICT standard experts, organises regularly an inspirational webinar - called walk & talk. The next ediation will be on quantum technologies. You'll get as main takeaways: Overview of Standards patterns in the field, Ongoing initiatives & Future Directions.
Quantum Technologies will make it possible to do things that might seem unthinkable today. With quantum, it will be possible to perform sophisticated computational tasks, like modelling biomolecular and chemical reactions, that the most powerful supercomputers cannot currently manage. Quantum will allow us to send sensitive information safely to anywhere, or even diagnose diseases quicker by looking inside cells.
Europe has a long-lasting tradition of excellence in quantum research. This legacy is brought forward with the Quantum Technologies Flagship, a large-scale, long-term research initiative funded by the EU that brings together research institutions, industry and public funders, consolidating and expanding European scientific leadership and excellence in this field.
This webinar will deal with the “State of the Art” in Quantum Technologies Standardisation, discuss European Policy and Strategies for development of adoption of Quantum Technologies within the Digital Single Market, presenting expert contributions from European and International Standards Development Organisations (SDOs).
Agenda
More information & registration on the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.